FIND DRUGS:

BRAND NAME GENERIC NAME INDICATION MANUFACTURERS COMPARE DRUGS

Publication of Clinical Trial Data is Delayed by Almost Two Years

Share this article:
Clinical Trials Published Almost Two Years After Completion
Clinical Trials Published Almost Two Years After Completion

(HealthDay News) -- Clinical trials are published, on average, almost two years after completion, with time to publication affected by the funding source, number of trial participants, and journal impact factor, according to a research letter published online March 4 in JAMA Internal Medicine.

Joseph S. Ross, M.D., M.H.S., from the Yale University School of Medicine in New Haven, Conn., examined the time to publication for a representative sample of clinical trials published in 2009, identified via ClinicalTrials.gov.

During the 2009 calendar year, the researchers found 1,336 trials published that were indexed via MEDLINE and linked to a ClinicalTrials.gov identifier. Most had more than 100 participants enrolled and were funded by nonprofit organizations. The median time to publication was 21 months (interquartile range, 13 to 32 months). Among trials funded by industry the time to publication was longer than for government- or nonprofit organization-funded trials (24 versus 20 months). There was a shorter time to publication for trials involving 1,000 or more participants than for those with 100 or fewer participants or 100 to 1,000 participants (18, 20, and 23 months, respectively). The journal impact factor affected time to publication, which was shorter for trials published in journals with an impact factor greater than 10 versus less than 10 (17 versus 23 months).

"Given the time required to publish results from these clinical trials, our findings support current federal initiatives requiring results reporting of clinical studies within 12 months of trial completion to ensure the timely dissemination of clinical science," the authors write.

Two authors disclosed financial ties to Medtronic; one author disclosed ties to United Healthcare.

Full Text (subscription or payment may be required)

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

CTA Community Poll

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in General Oncology News

Second List of 'Choosing Wisely' Oncology Guidelines Released

Second List of 'Choosing Wisely' Oncology Guidelines Released

ASTRO recommendations indicate treatment options that should be discussed before being prescribed.

Cancer Survival at All-Time High Due to Targeted Drugs

Cancer Survival at All-Time High Due to Targeted ...

But aging population and increasing obesity threaten progress, notes American Association for Cancer Research.

Half of Cancer Staff Believe Dignified Death Possible In-Center

Half of Cancer Staff Believe Dignified Death Possible ...

But 95 percent of palliative care staff indicate that patients die with dignity in their wards.